BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) granted inducement restricted stock units covering an aggregate of 30,700 shares to three newly hired employees, effective November 3, 2025.

The awards were approved by the compensation committee as inducements under Nasdaq Listing Rule 5635(c)(4) and are governed by the company’s Inducement Equity Incentive Plan and individual RSU agreements. The RSUs vest in four equal annual installments beginning on the one‑year anniversary of the grant, each installment subject to the employee’s continued service.

RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as of November 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What did BioCryst (BCRX) announce on November 5, 2025 about new-hire equity?

BioCryst announced inducement grants of restricted stock units totaling 30,700 shares to three newly hired employees, granted as of November 3, 2025.

How do the BioCryst (BCRX) RSUs vest and when does vesting begin?

The RSUs vest in four equal annual installments, with vesting beginning on the one‑year anniversary of the November 3, 2025 grant date, subject to continued service.

Under what rule were the BioCryst (BCRX) RSUs granted as inducements?

The RSUs were granted as inducements under Nasdaq Listing Rule 5635(c)(4).

Are the BioCryst (BCRX) RSUs subject to a plan or agreement?

Yes; the RSUs are subject to BioCryst’s Inducement Equity Incentive Plan and each recipient’s restricted stock unit agreement.

How many employees received inducement RSUs in the BioCryst (BCRX) announcement?

Three newly hired employees received the inducement RSU grants totaling 30,700 shares.